Treatment and Outcomes of Unifocal and Multifocal Osseous Pelvic Langerhans Cell Histiocytosis Lesions in a Pediatric Population

Parker Mitchell, Ekene U Ezeokoli, Neritan Borici, Eva Schleh, Nicole Montgomery, Parker Mitchell, Ekene U Ezeokoli, Neritan Borici, Eva Schleh, Nicole Montgomery

Abstract

Introduction Langerhans cell histiocytosis (LCH) is a rare, clonal disorder characterized by proliferation and tissue infiltration by myeloid dendritic cells, most commonly occurring in pediatric populations. It often manifests as skeletal lesions with possible pelvic involvement. Few studies have characterized and reviewed outcomes after treatment of isolated pelvic LCH lesions. Methods A retrospective single-institution review was conducted on diagnoses of patients younger than 18 with a diagnosis of unifocal or multifocal skeletal LCH lesions involving the pelvis. Clinical presentations, lesion sites, focal classification, radiographic findings, treatments, complications, and recurrence rates were reviewed. Results Twenty patients had unifocal or multifocal LCH pelvic lesions (11 males, nine females). The median age at diagnosis was 3.5 years (0.8-21.6). Eight cases (40%) involved unifocal lesions, and twelve (60%) involved multifocal lesions, with the most common associated skeletal disease occurring at the ilium. 100% of cases had a lytic bone lesion with no pathologic fractures. All cases were treated nonoperatively with chemotherapy medications, corticosteroids, or observation alone. 75% of cases were treated with chemotherapy with a 100% resolution rate. The median length of follow-up was 4.5 years (0.4-16.7). Conclusion Our study found that chemotherapy alone or chemotherapy with corticosteroid supplementation are appropriate options for unifocal pelvic LCH lesions. In contrast, pelvic lesions that are part of a multifocal presentation may be managed adequately with varied chemotherapy regimens. Corticosteroid therapy and observation alone may also be reasonable for a single organ system, multifocal, skeletal lesions that are anatomically accessible for biopsy and small in number or size.

Keywords: chemotherapy; hip; histiocytosis; langerhans; lch; lesion; pelvis.

Conflict of interest statement

The authors have declared that no competing interests exist.

Copyright © 2022, Mitchell et al.

Figures

Figure 1. 8-year-old female presenting with hip…
Figure 1. 8-year-old female presenting with hip and lower extremity pain (Case 14). (A) AP PET/CT demonstrating hyperintensity of the right ilium. (B) Axial CT demonstrating an osteolytic lesion at the right ilium.

References

    1. Clinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party. Kim BE, Koh KN, Suh JK, et al. J Pediatr Hematol Oncol. 2014;36:125–133.
    1. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Grois N, Pötschger U, Prosch H, et al. Pediatr Blood Cancer. 2006;46:228–233.
    1. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Haupt R, Minkov M, Astigarraga I, et al. Pediatr Blood Cancer. 2013;60:175–184.
    1. Solitary, late-onset, self-healing Langerhans cell histiocytosis. Murata S, Yoshida Y, Adachi K, Morita E, Yamamoto O. Acta Derm Venereol. 2011;91:103–104.
    1. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Minkov M. Paediatr Drugs. 2011;13:75–86.
    1. Late outcomes in children with Langerhans cell histiocytosis. Chow TW, Leung WK, Cheng FW, et al. Arch Dis Child. 2017;102:830–835.
    1. Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long-term survivors. Lau LM, Stuurman K, Weitzman S. Pediatr Blood Cancer. 2008;50:607–612.
    1. Eosinophilic granuloma of bone. Slater JM, Swarm OJ. Med Pediatr Oncol. 1980;8:151–164.
    1. Langerhans'-cell histiocytosis in adults. Baumgartner I, von Hochstetter A, Baumert B, et al. Med Pediatr Oncol. 1997;28:9–14.
    1. Langerhans cell histiocytosis of the shoulder girdle, pelvis and extremities: a review of radiographic and MRI features in 85 cases. Singh J, Rajakulasingam R, Saifuddin A. Skeletal Radiol. 2020;49:1925–1937.
    1. Langerhans cell histiocytosis: another cause of a fluid-fluid level within an appendicular bony lesion. Rama KVV, Leong MY, Tan AM, Quan DLW, Teo EL. BJR Case Rep. 2016;2:20150408.
    1. MRI and clinical features of Langerhans cell histiocytosis (LCH) in the pelvis and extremities: can LCH really look like anything? Samet J, Weinstein J, Fayad LM. Skeletal Radiol. 2016;45:607–613.
    1. Utilization of chemical shift MRI in the diagnosis of disorders affecting pediatric bone marrow. Winfeld M, Ahlawat S, Safdar N. Skeletal Radiol. 2016;45:1205–1212.
    1. Multifocal Langerhans cell histiocytosis with infiltrative pelvic lesions: PET/CT imaging. Nguyen BD, Roarke MC, Chivers SF. Clin Nucl Med. 2010;35:824–826.
    1. Langerhans cell histiocytosis of bone in an adult: a case report. Christopher Z, Binitie O, Henderson-Jackson E, Perno J, Makanji RJ. Radiol Case Rep. 2018;13:310–314.
    1. Radiologic findings of adult pelvis and appendicular skeletal Langerhans cell histiocytosis in nine patients. Song YS, Lee IS, Yi JH, Cho KH, Kim DK, Song JW. Skeletal Radiol. 2011;40:1421–1426.
    1. Unifocal Langerhans cell histiocytosis of bone: percutaneous navigational bipolar radiofrequency ablation for curative treatment. Tomasian A, Hillen TJ, Jennings JW. Clin Imaging. 2021;72:55–57.
    1. Clinical features and treatment of Langerhans cell histiocytosis. Rodriguez-Galindo C. Acta Paediatr. 2021;110:2892–2902.
    1. Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis. Krooks J, Minkov M, Weatherall AG. J Am Acad Dermatol. 2018;78:1035–1044.
    1. Clinical characteristics and treatment of Langerhans cell histiocytosis. Monsereenusorn C, Rodriguez-Galindo C. Hematol Oncol Clin North Am. 2015;29:853–873.
    1. Langerhans cell histiocytosis in children: a retrospective case series of 126 cases. Dhar S, Srinivas SM, Dhar S, et al. Pediatr Dermatol. 2020;37:1085–1089.
    1. Isolated Langerhans cell histiocytosis bone lesion in pediatric patients: systematic review and treatment algorithm. Bezdjian A, Alarfaj AA, Varma N, Daniel SJ. Otolaryngol Head Neck Surg. 2015;153:751–757.
    1. Intralesional infiltration of corticosteroids in localized Langerhans' cell histiocytosis. Egeler RM, Thompson RC Jr, Voûte PA, Nesbit ME Jr. J Pediatr Orthop. 1992;12:811–814.
    1. Radiologic findings of scapular Langerhans cell histiocytosis successfully treated with CT-guided corticosteroid injection. Sahin C, Ucpinar BA, Oc Y, Kabukcuoglu F. J Coll Physicians Surg Pak. 2020;30:754–756.
    1. Thoracoscopic rib resection in children. Alshammari DM, Talon I, Rod J, et al. J Laparoendosc Adv Surg Tech A. 2018;28:106–110.
    1. Approaches to treatment of unifocal Langerhans cell histiocytosis: is biopsy alone enough? Rivera JC, Wylie E, Dell'Orfano S, et al. J Pediatr Orthop. 2014;34:820–824.
    1. Percutaneous techniques for the diagnosis and treatment of localized Langerhans-cell histiocytosis (eosinophilic granuloma of bone) Yasko AW, Fanning CV, Ayala AG, Carrasco CH, Murray JA. J Bone Joint Surg Am. 1998;80:219–228.
    1. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Howarth DM, Gilchrist GS, Mullan BP, et al. Cancer. 1999;85:2278–2290.
    1. Skeletal involvement in children with Langerhans cell histiocytosis: healing, complications, and functional outcome. Abdelaal AH, Sedky M, Gohar S, Zaki I, Salama A, Hassanain O, El Ghoneimy AM. SICOT J. 2020;6:28.

Source: PubMed

3
구독하다